Sandra Calvin Sells 4,333 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 4,333 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $32.12, for a total transaction of $139,175.96. Following the completion of the sale, the chief accounting officer directly owned 49,080 shares of the company’s stock, valued at approximately $1,576,449.60. This trade represents a 8.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sandra Calvin also recently made the following trade(s):

• On Wednesday, December 24th, Sandra Calvin sold 7,402 shares of Travere Therapeutics stock. The stock was sold at an average price of $40.00, for a total transaction of $296,080.00.

Travere Therapeutics Stock Down 3.5%

NASDAQ TVTX opened at $31.68 on Thursday. The company has a debt-to-equity ratio of 4.23, a quick ratio of 2.71 and a current ratio of 2.75. The firm has a 50-day simple moving average of $34.02 and a 200 day simple moving average of $27.79. Travere Therapeutics, Inc. has a twelve month low of $12.91 and a twelve month high of $42.13. The stock has a market cap of $2.83 billion, a PE ratio of -29.89, a PEG ratio of 1.00 and a beta of 0.83.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $47.00 price objective on shares of Travere Therapeutics in a research report on Friday, November 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Piper Sandler increased their price objective on shares of Travere Therapeutics from $26.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. TD Cowen reaffirmed a “buy” rating on shares of Travere Therapeutics in a report on Friday, October 31st. Finally, Citigroup upped their target price on shares of Travere Therapeutics from $34.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $38.86.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Bank of America Securities reaffirmed its Buy rating on Travere, which supports demand from institutional investors and may limit downside pressure. Bank of America Securities Sticks to Its Buy Rating for Travere Therapeutics (TVTX)
• Neutral Sentiment: Travere will present at the Guggenheim Emerging Outlook: Biotech Summit on Feb. 11 (live webcast/replay available). The event gives management a platform to update investors and could provide near-term catalysts if new data or guidance are disclosed. Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
• Negative Sentiment: Heavy insider selling on Feb. 3 — including CEO Eric Dube (100,087 shares) and multiple senior officers (CFO, CAO and others) — represents a large, coordinated reduction in holdings that can trigger investor concern and short-term selling pressure. These SEC‑filed sales were disclosed in multiple Form 4s and media reports. Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CAO Sells 4,333 Shares of Stock

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Travere Therapeutics in the 4th quarter worth about $558,000. RFG Advisory LLC acquired a new position in Travere Therapeutics in the fourth quarter valued at about $1,633,000. Garner Asset Management Corp bought a new stake in Travere Therapeutics during the fourth quarter worth about $69,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of Travere Therapeutics during the fourth quarter worth approximately $213,000. Finally, State of New Jersey Common Pension Fund D bought a new position in shares of Travere Therapeutics in the fourth quarter valued at approximately $1,104,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.